Pulse Biosciences (PLSE) is back under the spotlight after reporting wider second quarter losses and launching a $75 million at the market equity offering, alongside ongoing progress in its atrial fibrillation nsPFA program.

The latest earnings miss and follow-on equity offering come after a sharp run-up in Pulse Biosciences' share price, with a 63.1% 1-month share price return and a very strong year-to-date share price return alongside a very large 3-year total shareholder return. This suggests momentum has been strong while valuation checks now point to a richer pricing of the stock.

If this kind of rapid re-rating has your attention, it can be useful to see what else is moving in related areas and uncover 40 healthcare AI stocks

Pulse Biosciences now combines an ambitious nsPFA pipeline with a share price that has moved ahead of the latest analyst target. The key issue for you is whether the business strength still aligns with today’s valuation.

Most Popular Narrative: 14.1% Overvalued

Pulse Biosciences closed at $46.79 compared with a narrative fair value of $41.00. This frames the latest move above recent analyst assumptions.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Want to see what underpins that fair value gap? The narrative leans on rapid revenue expansion, a sharp margin shift and a future earnings multiple that assumes sustained commercial traction.

Result: Fair Value of $41.00 (OVERVALUED)

However, Pulse Biosciences still faces key hurdles, including ongoing losses of $80.1 million and the execution risk around converting its nsPFA pipeline into meaningful revenue.

Next Steps

With sentiment clearly split on Pulse Biosciences, it is worth moving quickly to check the data for yourself and decide where you stand. To see both sides in one place, take a closer look at the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Pulse Biosciences?

If Pulse Biosciences has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that match clear, data driven criteria and keep your edge.

• Target potential mispricings by scanning companies that look attractively valued on key fundamentals through the 53 high quality undervalued stocks.
• Strengthen your income focus by reviewing companies that feature reliable payouts in the 10 dividend fortresses.
• Prioritise resilience by checking stocks that show lower overall risk profiles using the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.